Needham & Co reiterates their buy rating on Alnylam Pharmaceuticals (Nasdaq: ALNY) with a new $26 price target., followng the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE